ライフサイエンスコーパス: topiramate

1 , tiagabine, valproic acid, lamotrigine, and topiramate).

2 riety of therapies, including gabapentin and topiramate.

3 , gabapentin, lamotrigine, oxcarbazepine, or topiramate.

4 ings for baclofen, modafinil, tiagabine, and topiramate.

5 , namely baclofen, modafinil, tiagabine, and topiramate.

6 sm underlying the anticonvulsant activity of topiramate.

7 tes: felbamate, gabapentin, lamotrigine, and topiramate.

8 tin, lamotrigine, felbamate, vigabatrin, and topiramate.

9 more than 5 times higher in patients taking topiramate.

10 r bupropion and 2.59 (95% CI, 1.56-4.30) for topiramate.

11 bupropion and 5.30 (95% CI, 2.54-11.04) for topiramate.

12 t significantly increased for acamprosate or topiramate.

13 648 randomly matched patients who never took topiramate.

14 he risk of glaucoma with first-time users of topiramate.

15 , gabapentin, lamotrigine, oxcarbazepine, or topiramate.

16 anged from 7.3% for lamotrigine to 18.5% for topiramate.

17 (HR, 1.65; 95% CI, 1.25-2.19), compared with topiramate.

18 3-0.97]), gabapentin (0.65 [0.52-0.80]), and topiramate (0.64 [0.52-0.79]), and had a non-significant

19 pine against lamotrigine (0.91 [0.77-1.09]), topiramate (0.86 [0.72-1.03]), and oxcarbazepine (0.92 [

20 The marketed drug topiramate ( 1) is a moderate inhibitor of carbonic anhy

21 Topiramate (1) and its sulfamide analogue 4, and 4,5-cyc

22 he clinically efficacious antiepileptic drug topiramate (1), a unique sugar sulfamate anticonvulsant

23 conformation, were nearly twice as potent as topiramate (1).

24 than both lamotrigine (1.55 [1.07-2.24] and topiramate (1.89 [1.32-2.70]).

25 r 15 mg phentermine/92 mg controlled-release topiramate (15/92)] to complete a total of 108 wk.

26 (1 mg per kilogram of body weight per day), topiramate (2 mg per kilogram per day), and placebo in c

27 8.0; p<0.0001) with phentermine 7.5 mg plus topiramate 46.0 mg, and 687 (70%; 9.0, 7.3 to 11.1; p<0.

28 placebo, 19 (4%) to phentermine 7.5 mg plus topiramate 46.0 mg, and 73 (7%) to phentermine 15.0 mg p

29 d to placebo, 498 to phentermine 7.5 mg plus topiramate 46.0 mg, and 995 to phentermine 15.0 mg plus

30 assigned to placebo, phentermine 7.5 mg plus topiramate 46.0 mg, and phentermine 15.0 mg plus topiram

31 assigned to placebo, phentermine 7.5 mg plus topiramate 46.0 mg, and phentermine 15.0 mg plus topiram

32 placebo, once-daily phentermine 7.5 mg plus topiramate 46.0 mg, or once-daily phentermine 15.0 mg pl

33 ts meeting entry criteria were randomized to topiramate (50, 100, or 200 mg/d) or placebo.

34 7.5 mg phentermine/46 mg controlled-release topiramate (7.5/46), or 15 mg phentermine/92 mg controll

35 compared with placebo at 1 year-phentermine-topiramate, 8.8 kg (95% CrI, -10.20 to -7.42 kg); liragl

36 mg, and 73 (7%) to phentermine 15.0 mg plus topiramate 92.0 mg had depression-related adverse events

37 0 mg, or once-daily phentermine 15.0 mg plus topiramate 92.0 mg in a 2:1:2 ratio in 93 centres in the

38 ramate 46.0 mg, and phentermine 15.0 mg plus topiramate 92.0 mg, respectively), paraesthesia (20 [2%]

39 ramate 46.0 mg, and phentermine 15.0 mg plus topiramate 92.0 mg, respectively.

40 46.0 mg, and 995 to phentermine 15.0 mg plus topiramate 92.0 mg; 979, 488, and 981 patients, respecti

41 1.1; p<0.0001) with phentermine 15.0 mg plus topiramate 92.0 mg; for >/=10% weight loss, the correspo

42 94%, placebo: 46%) and binge day frequency (topiramate: 93%, placebo: 46%) and with a significantly

43 antly greater reductions in binge frequency (topiramate: 94%, placebo: 46%) and binge day frequency (

44 Topiramate, a fructopyranose derivative, was superior to

45 natal seizures, we evaluated the efficacy of topiramate, a structurally novel anticonvulsant drug rec

46 Topiramate, a sulphamate fructopyranose derivative, migh

47 of the mesocorticolimbic dopamine system by topiramate-a glutamate receptor antagonist and gamma-ami

48 The results indicate that administration of topiramate after experimental status epilepticus can att

49 Patients receiving topiramate also had lower concentrations of the liver en

50 er forms of cognitive behavioral therapy and topiramate also increased abstinence and reduced binge-e

51 Topiramate also partially depressed predominantly AMPA-r

52 Topiramate also was associated, significantly more than

53 We hypothesized that topiramate, an anticonvulsant with multiple mechanisms o

54 k has suggested efficacy and tolerability of topiramate and fluphenazine, but more rigorous studies a

55 Phentermine-topiramate and liraglutide were associated with the high

56 Valproate is better tolerated than topiramate and more efficacious than lamotrigine, and sh

57 Cyclic sulfate 2, like topiramate and phenytoin, did not interfere with seizure

58 rolled 12-week clinical trial comparing oral topiramate and placebo for treatment of 150 individuals

59 ong individual anticonvulsants compared with topiramate and secondarily carbamazepine.

60 Newer medical treatment options like topiramate and surgical treatment options like stereotac

61 Topiramate and trazodone have limited evidence supportin

62 pared initiating treatment with lamotrigine, topiramate and valproate in patients diagnosed with gene

63 xetine, 5 studies of bupropion, 9 studies of topiramate, and 1 study each of sertraline and zonisamid

64 Ondansetron, naltrexone, topiramate, and baclofen are examples.

65 Three other drugs, bupropion, topiramate, and ciliary neurotrophic factor, are undergo

66 orcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide, compared with placebo, were

67 Lamotrigine, gabapentin, topiramate, and oxcarbazepine are available for use as m

68 tide; in the USA, lorcaserin and phentermine/topiramate are also available.

69 Lamotrigine and topiramate are also thought to possess broad spectrum ac

70 ol, the beta-blocker, and the anticonvulsant topiramate are effective for migraine prevention.

71 utide, naltrexone/bupropion, and phentermine/topiramate are new agents that have been recently approv

72 Both bupropion and topiramate are widely prescribed drugs.

73 The importance of topiramate as a cause of secondary angle closure has rec

74 (P<.05) occurred within the first month with topiramate at 100 and 200 mg/d.

75 creased significantly for patients receiving topiramate at 100 mg/d (-2.1, P =.008) and topiramate at

76 toneal injections of either vehicle (n=6) or topiramate at 20 mg/kg (n=6), 40 mg/kg (n=7) or 80 mg/kg

77 g topiramate at 100 mg/d (-2.1, P =.008) and topiramate at 200 mg/d (-2.4, P<.001) vs placebo (-1.1).

78 esponder rate was significantly greater with topiramate at 50 mg/d (39%, P =.01), 100 mg/d (49%, P<.0

79 Weight loss due to topiramate at 6 months was 6.5% (CI, 4.8% to 8.3%) of pr

80 These findings support the use of topiramate at a daily dose of 200 mg to reduce heavy dri

81 Administration of topiramate at each dose was associated with a significan

82 pal neurons of the rat basolateral amygdala, topiramate at low concentrations (IC50, approximately 0.

83 We further demonstrate that topiramate attenuates AMPA-kainate receptor-mediated cel

84 nts who received their first prescription of topiramate between 2001 and 2007.

85 domly assigned to valproate, lamotrigine, or topiramate between Jan 12, 1999, and Aug 31, 2004, and f

86 was also decreased by the antiepileptic drug topiramate, but not by carbamazepine.

87 Hypothetically, topiramate can improve drinking outcomes among alcohol-d

88 The combination of phentermine and topiramate caused significant weight loss, slowed gastri

89 tricyclic antidepressants, anticonvulsants (topiramate), coenzyme Q-10, and L-carnitine.

90 cified mixed-model analysis also showed that topiramate compared with placebo decreased the percentag

91 d over the course of double-blind treatment, topiramate, compared with placebo, improved the odds of

92 At study end, participants on topiramate, compared with those on placebo, had 2.88 (95

93 mood stabilizers, whereas carbamazepine and topiramate continued to produce positive results, olanza

94 and safety of two doses of phentermine plus topiramate controlled-release combination as an adjunct

95 Topiramate did not alter the degree of facilitation in p

96 raines (<15 headaches per month) included topiramate (difference in headaches per month, -0.71; 95

97 patients (three receiving placebo, six given topiramate) discontinued because of adverse events.

98 use of several antiepileptic agents such as topiramate, disodium valproate, levetiracetam, the antih

99 Notably, protective doses of NBQX and topiramate do not affect normal maturation and prolifera

100 Median topiramate dose was 212 mg/day (range=50-600).

101 to the side of stimulation at the two higher topiramate doses only.

102 weeks to a maximum dose of 60 mg daily, and topiramate doses were titrated over 6 weeks to a maximum

103 , in animals that had seizures suppressed by topiramate during acute hypoxia, there were no long-term

104 Topiramate effectively suppressed acute seizures induced

105 s, such as carbamazepine, oxcarbazepine, and topiramate, enhances hepatic cytochrome P450 3A4 (CYP3A4

106 Seventy-five participants received topiramate (escalating dose of 25 mg/d to 300 mg/d), and

107 150 individuals, 75 were assigned to receive topiramate (escalating dose of 25-300 mg per day) and 75

108 9% for top-dose (15/92 mg) phentermine plus topiramate-extended release at 1 year.

109 and 67% to 70% for top-dose phentermine plus topiramate-extended release.

110 extended-release mixed amphetamine salts and topiramate group (33.3%) than in placebo group (16.7%).

111 ents of altered mood, and one patient in the topiramate group had a suicide attempt.

112 the amitriptyline group, 55% of those in the topiramate group, and 61% of those in the placebo group

113 (132 in the amitriptyline group, 130 in the topiramate group, and 66 in the placebo group).

114 % vs. 8%) and weight loss (8% vs. 0%) in the topiramate group.

115 e events resulting in discontinuation in the topiramate groups included paresthesia, fatigue, and nau

116 the 100-mg/d (P =.01) and 200-mg/d (P =.005) topiramate groups.

117 the 100-mg/d (P =.003) and 200-mg/d (P<.001) topiramate groups.

118 Patients who received amitriptyline or topiramate had higher rates of several adverse events th

119 Topiramate has been shown to reduce drinking and heavy d

120 Amphetamine and topiramate have both shown promise for the treatment of

121 nded release combination of phentermine with topiramate have recently gained approval.

122 ure, valproate was significantly better than topiramate (hazard ratio 1.57 [95% CI 1.19-2.08]), but t

123 day: WMD, -1.02; 95% CI, -1.77 to -0.28) and topiramate (% heavy drinking days: WMD, -9.0%; 95% CI, -

124 ed trial of extended-release phentermine and topiramate in 24 patients to validate associations betwe

125 significant difference between valproate and topiramate in either the analysis overall or for the sub

126 s evaluated the efficacy and tolerability of topiramate in heavy drinkers whose treatment goal was to

127 The objective of this study was to evaluate topiramate in the treatment of binge eating disorder ass

128 Topiramate-induced differences in craving were also sign

129 Topiramate is a promising treatment for alcohol dependen

130 To determine if topiramate is a safe and efficacious treatment for alcoh

131 Topiramate is a widely used antiepileptic agent whose me

132 Topiramate is an antiepileptic agent associated with wei

133 that the mechanism of protective efficacy of topiramate is caused at least in part by attenuation of

134 d trials suggest that the antiepileptic drug topiramate is effective for migraine prevention.

135 The anticonvulsant topiramate is effective for migraine prevention.

136 evidence that the combination of MAS-ER and topiramate is efficacious in promoting abstinence in coc

137 Topiramate is more efficacious than placebo at increasin

138 soflurane, desflurane), antiepileptic drugs (topiramate, lacosamide, pregabalin, levetiracetam), hypo

139 Our results suggest that topiramate may have clinical potential as a therapeutic

140 ine, and tiagabine, compared with the use of topiramate, may be associated with an increased risk of

141 Up to 300 mg/d of topiramate (n = 183) or placebo (n = 188), along with a

142 Topiramate (n = 71) or placebo (n = 71) in escalating do

143 0 kg/m(2)) were randomly assigned to receive topiramate (N=30) or placebo (N=31).

144 signed to receive 12 weeks of treatment with topiramate (N=67), at a maximal daily dose of 200 mg, or

145 t, and 2 studies compared different doses of topiramate; none of these trials showed significant diff

146 ss vs 75% of participants taking phentermine-topiramate (odds ratio [OR], 9.22; 95% credible interval

147 Topiramate, onabotulinum toxin type A, gabapentin, petas

148 release mixed amphetamine salts (MAS-ER) and topiramate or placebo for 12 weeks under double-blind co

149 oxy-6-nitro-7-sulfonyl-benzo[f]quinoxaline), topiramate, or GYKI-53773 [(1)-1-(4-aminophenyl)-3-acety

150 and adolescent migraine with amitriptyline, topiramate, or placebo over a period of 24 weeks.

151 amate vs. placebo, P=0.48; amitriptyline vs. topiramate, P=0.49).

152 Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to lifestyle mod

153 ted rate ratios were computed for bupropion, topiramate (positive control group drug), and esomeprazo

154 propion, bupropion, probably fluoxetine, and topiramate promote modest weight loss when given along w

155 avioral therapy, lisdexamfetamine, SGAs, and topiramate reduced binge eating and related psychopathol

156 Topiramate reduced weight and increased sympathetic nerv

157 ed psychopathology, and lisdexamfetamine and topiramate reduced weight in adults with binge-eating di

158 the risk of glaucoma among current users of topiramate (RR = 1.23 [95% confidence interval (CI), 1.0

159 In a European American subsample (N=122), topiramate's effect on heavy drinking days was significa

160 ate the kainate receptor in the mechanism of topiramate's effects on heavy drinking.

161 Topiramate showed significant efficacy in migraine preve

162 erence [SMD], -0.20; 95% CI, -0.91 to 0.31), topiramate (SMD, 0.20; 95% CI, -0.36 to 0.76), or amitri

163 Topiramate (Topamax) and phentermine have long been appr

164 valproate (VPA) 0.74 (0.10 to 1.38) p=0.02; topiramate (TPM) -2.30 (-4.27 to -0.33) p=0.02.

165 It was hypothesized that topiramate-treated patients would be better able to achi

166 The mean weight loss for topiramate-treated subjects who completed the study was

167 y drinkers who are likely to respond well to topiramate treatment and provide an important personaliz

168 Topiramate treatment significantly reduced heavy drinkin

169 double-blind, flexible-dose (25-600 mg/day) topiramate trial, 61 outpatients (53 women, eight men) w

170 Topiramate (up to 300 mg per day) is more efficacious th

171 medication compliance enhancement treatment, topiramate (up to 300 mg/d) was superior to placebo at n

172 Topiramate use in Taiwan was associated with a significa

173 ring drug therapy was observed among current topiramate users (RR = 1.09 [95% CI, 0.80-1.61]).

174 the consensus effectiveness of lamotrigine, topiramate, valproate, aripiprazole, olanzapine, and ome

175 Topiramate, valproate, propranolol, amitriptyline, and m

176 ntin, lamotrigine, levetiracetam, tiagabine, topiramate, vigabatrin, and zonisamide do not induce the

177 abapentin vs carbamazepine, 0.71, 0.59-0.86; topiramate vs carbamazepine, 0.81, 0.68-0.98).

178 Adverse events that were more common with topiramate vs placebo, respectively, included paresthesi

179 bo group (amitriptyline vs. placebo, P=0.26; topiramate vs. placebo, P=0.48; amitriptyline vs. topira

180 Topiramate was also associated with significantly greate

181 Compared with placebo, topiramate was associated with a significantly greater r

182 Topiramate was efficacious and relatively well tolerated

183 We aimed to see whether topiramate was more effective than placebo as a treatmen

184 Using an intent-to-treat analysis, topiramate was more efficacious than placebo at increasi

185 reating all dropouts as relapse to baseline, topiramate was more efficacious than placebo at reducing

186 The anticonvulsant topiramate was recently shown to be effective for migrai

187 ; weight loss in response to phentermine and topiramate was significantly associated with calorie int

188 Topiramate was titrated by 25 mg/wk for 8 weeks to the a

189 ate ratios (RRs) for current and past use of topiramate were computed.

190 ial confounding factors, patients prescribed topiramate were found to have a 7.41-fold (95% confidenc

191 The most common reasons for discontinuing topiramate were headache (N=3) and paresthesias (N=2).

192 Sodium valproate, benzodiazepines and topiramate were reported as being the most helpful medic

193 that the clinically available anticonvulsant topiramate, when administered post-insult in vivo, is pr

194 The combination of phentermine and topiramate, with office-based lifestyle interventions, m

195 ypothesis that the combination of MAS-ER and topiramate would be superior to placebo in achieving 3 w